These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 3871244)
21. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP. Kindt MV; Youngster SK; Sonsalla PK; Duvoisin RC; Heikkila RE Eur J Pharmacol; 1988 Feb; 146(2-3):313-8. PubMed ID: 3131149 [TBL] [Abstract][Full Text] [Related]
22. Depletion of cardiac norepinephrine in rats and mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Fuller RW; Hahn RA; Snoddy HD; Wikel JH Biochem Pharmacol; 1984 Oct; 33(19):2957-60. PubMed ID: 6333240 [TBL] [Abstract][Full Text] [Related]
23. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs. Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564 [TBL] [Abstract][Full Text] [Related]
24. Studies on the acute and long-term changes in dopamine and noradrenaline metabolism in mouse brain following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Pileblad E; Carlsson A Pharmacol Toxicol; 1988 Apr; 62(4):213-22. PubMed ID: 3260379 [TBL] [Abstract][Full Text] [Related]
25. Effects of amfonelic acid, alpha-methyltyrosine, Ro 4-1284 and haloperidol pretreatment on the depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Fuller RW; Hemrick-Luecke SK Res Commun Chem Pathol Pharmacol; 1985 Apr; 48(1):17-25. PubMed ID: 3873102 [TBL] [Abstract][Full Text] [Related]
26. Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents. Sundström E; Samuelsson EB Pharmacol Toxicol; 1997 Nov; 81(5):226-31. PubMed ID: 9396088 [TBL] [Abstract][Full Text] [Related]
27. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. Sagi Y; Weinstock M; Youdim MB J Neurochem; 2003 Jul; 86(2):290-7. PubMed ID: 12871570 [TBL] [Abstract][Full Text] [Related]
28. Effect of MPTP and its pyridinium metabolites on monoamine uptake and on central catecholamine neurons in mice. Jonsson G; Nwanze E; Luthman J; Sundström E Acta Physiol Scand; 1986 Oct; 128(2):187-94. PubMed ID: 3535380 [TBL] [Abstract][Full Text] [Related]
29. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B. Finnegan KT; Irwin I; Delanney LE; Langston JW J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075 [TBL] [Abstract][Full Text] [Related]
31. Comparison of intra- and extrasynaptosomal monoamine oxidase-A and -B activities in the striatum and frontal cortex of two mice strains with different sensitivities to the neurotoxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Stenström A; Sundström E; Fowler CJ Pharmacol Toxicol; 1989 Mar; 64(3):276-81. PubMed ID: 2786196 [TBL] [Abstract][Full Text] [Related]
32. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Heikkila RE; Duvoisin RC; Finberg JP; Youdim MB Eur J Pharmacol; 1985 Oct; 116(3):313-7. PubMed ID: 3935467 [TBL] [Abstract][Full Text] [Related]
33. Correlation of MPTP neurotoxicity in vivo with oxidation of MPTP by the brain and blood-brain barrier in vitro in five rat strains. Riachi NJ; Behmand RA; Harik SI Brain Res; 1991 Jul; 555(1):19-24. PubMed ID: 1933326 [TBL] [Abstract][Full Text] [Related]
34. Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2'-methyl-MPTP. Sziráki I; Kardos V; Patthy M; Pátfalusi M; Gaál J; Solti M; Kollár E; Singer J J Neural Transm Suppl; 1994; 41():207-19. PubMed ID: 7931228 [TBL] [Abstract][Full Text] [Related]
35. Monoamine oxidase B(MAO-B) is the major catalyst for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation in human brain and other tissues. Glover V; Gibb C; Sandler M Neurosci Lett; 1986 Feb; 64(2):216-20. PubMed ID: 3083305 [TBL] [Abstract][Full Text] [Related]
36. Neurochemical investigations in vitro with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in preparations of rat brain. Markstein R; Lahaye D Eur J Pharmacol; 1984 Nov; 106(2):301-11. PubMed ID: 6335691 [TBL] [Abstract][Full Text] [Related]
37. A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor. Matsumoto J; Takahashi T; Agata M; Toyofuku H; Sasada N Jpn J Pharmacol; 1994 May; 65(1):51-7. PubMed ID: 8089930 [TBL] [Abstract][Full Text] [Related]
38. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity. Kinemuchi H; Arai Y; Toyoshima Y Neurosci Lett; 1985 Jul; 58(2):195-200. PubMed ID: 3876524 [TBL] [Abstract][Full Text] [Related]